Skip to content

Bioalmanac

Noopept

Omberacetam · N-phenylacetyl-L-prolylglycine ethyl ester · GVS-111

Approved for another indication

Status reviewed 18 Aug 2026

A Russian prescription nootropic, registered there since 1996. Not a peptide despite the name, and unapproved everywhere else.

Storage

Freeze-dried powder
Tablets or powder at room temperature, dry and out of light.
After mixing
Not applicable. This is taken orally.

Dose ranges reported in sources

Descriptions of what sources report, not recommendations.

GoalRangeFrequencySource
Registered Russian dosing10000–30000 mcg10 mg two or three times daily, in courses of 6 to 8 weeksPublished review

When to stop

  • Irritability, agitation or sleep disturbance that does not settle.
  • Raised blood pressure. Measure it rather than guessing.
  • Persistent headache.
  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.

A registered prescription medicine in Russia since 1996 for cognitive impairment following stroke or injury. Not approved in the United States or the European Union, and controlled in the United Kingdom under the Psychoactive Substances Act.

Arithmetic on values you enter. Not medical advice. Not reviewed by a clinician. · bioalmanac.com/peptides/noopept

Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.